Location:

Local - Colorado

Add to Favorites | Subscribe | Share

Filters:

  • (Press "esc" to clear)

Science

Channels:

Global Warming, Climate Change, Geology

New Approach to Geoengineering Simulations Is Significant Step Forward

Using a sophisticated computer model, scientists have demonstrated for the first time that a new research approach to geoengineering could potentially be used to limit Earth’s warming to a specific target while reducing some of the risks and concerns identified in past studies, including uneven cooling of the globe.

Science

Channels:

New Approach to Geoengineering Simulations Is Significant Step Forward

Using a sophisticated computer model, scientists have demonstrated for the first time that a new research approach to geoengineering could potentially be used to limit Earth’s warming to a specific target while reducing some of the risks and concerns identified in past studies, including uneven cooling of the globe.

Medicine

Channels:

cancer glucose, CDK8, cdk8 cancer, joaquin espinosa, matthew galbraith, university of colorado cancer center, warburg effect

Study Finds a New Way to Shut Down Cancer Cells’ Ability to Consume Glucose

Many cancers depend on glucose consumption for energy, but good pharmacological targets to stop cancers’ ability to uptake and metabolize glucose are missing. CU Cancer Center study finally identifies a way to restrict the ability of cancer to use glucose for energy.

Medicine

Channels:

RECIST, recist criteria, ross camidge, rustain morgan

Important New Insights Into RECIST Criteria Measuring Cancer’s Response to Treatment

Rustain.Morgan.jpg

CU Cancer Center study examines current RECIST guidelines in an effort to bring them up to speed with new complexities presented by the latest targeted therapies.

Medicine

Life

Social and Behavioral Sciences

Channels:

Time Change, Sleep

Sleep Researcher Available to Discuss How This Weekend's Time Change Can Be Good for Your Health

Medicine

Channels:

alisertib, Cancer clinical trial, Jennifer Diamond, lindsey davis, TAK-228, triple-negative breast cancer, university of colorado cancer center

In the Lab and in the Clinic, Alisertib with TAK-228 Excels Against Solid Tumors, Including Triple-Negative Breast Cancer

Jenn.Diamond.jpg

Two University of Colorado Cancer Center studies presented this weekend at AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Meeting show that using the drug alisertib along with the drug TAK-228 is more effective against triple-negative breast cancer and solid tumors than either drug alone.

Medicine

Channels:

sleep and children, Electronics, blue light-emitting diodes

Children Uniquely Vulnerable to Sleep Disruption From Screens, New Paper Suggests

A new paper in the November issue of Pediatrics spells out why children and teens are particularly sensitive to the sleep-disrupting impact of electronics

Science

Channels:

CU Boulder Breaks Ground on New $82.5 Million Aerospace Engineering Building

Aerospace_Groundbreaking.CC18.JPG

The University of Colorado Boulder broke ground today on a new $82.5 million aerospace engineering building complete with an indoor flight environment for unmanned aircraft that will ensure the nationally ranked program continues to drive innovation into the future.

Life

Social and Behavioral Sciences

Channels:

$5.5 Million Study to Probe Impact of Marijuana Legalization on Use, Behavior, Mental Health

As more states consider legalizing recreational marijuana, University of Colorado researchers are launching a study funded by the National Institute on Drug Abuse (NIDA) to examine the impact legalization has on career fulfillment, family life, and substance use.

Medicine

Channels:

AACR, Adriana Estrada, egfr exon 20, egfr+ lung cancer, lung cancer clinical trials, Robert Doebele, tarloxitinib, university of colorado cancer center

Tarloxitinib Puts Tumor-Seeking Tail on Anti-EGFR Drug to Precisely Target Lung Cancer

University of Colorado Cancer Center study being presented October 28 at the AACR-NCI-EORTC International Conference on Molecular Targets: By pairing an anti-EGFR drug with a “tail” that only activates the drug when it is very near tumor cells, tarloxitinib brings the drug to tumors while keeping concentrations safe in surrounding tissues.







Chat now!